CMC and Morphotek Inc. sign development and clinical supply agreement for therapeutic antibody to treat melanoma.

By:Diana Morgan

COPENHAGEN, Denmark, June 1st, 2007
CMC Biopharmaceuticals A/S (CMC), a leading provider of contract bio-manufacturing services to the biopharmaceutical industry, announced today it has entered into an agreement with Morphotek Inc, a subsidiary of the Japanese company, Eisai Co., Ltd for the development, GMP manufacture and regulatory documentation support of MORAb-028, a therapeutic antibody targeting advanced melanoma and other cancers.

Read the entire pdf press release.